ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0043

Clinical Outcome and Antibody Response in COVID-19-Positive Pediatric Kidney and Liver Transplant Recipients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Talgam Horshi, Efrat, Assuta Ashdod Hospital, Ashdod, South, Israel
  • Mozer Glassberg, Yael, Schneider Children's Medical Center of Israel, Petah Tikva, Israel
  • Waisbourd-Zinman, Orith, Schneider Children's Medical Center of Israel, Petah Tikva, Israel
  • Ashkenazi-Hoffnung, Liat, Schneider Children's Medical Center of Israel, Petah Tikva, Israel
  • Haskin, Orly, Schneider Children's Medical Center of Israel, Petah Tikva, Israel
  • Levi, Shelly Shlomit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel
  • Hamdani, Gilad, Schneider Children's Medical Center of Israel, Petah Tikva, Israel
  • Landau, Daniel, Schneider Children's Medical Center of Israel, Petah Tikva, Israel
  • Alfandary, Hadas, Schneider Children's Medical Center of Israel, Petah Tikva, Israel
Background

<div style="direction: ltr;">The COVID-19 pandemic has profoundly impacted transplantation activity worldwide. Nevertheless, data on the clinical and laboratory features of SARS-CoV-2 infection in pediatric recipients of solid organ transplant (SOT) recipients are scarce.</div>

Methods

<div style="direction: ltr;">We describe clinical and laboratory manifestations, including serologic response, and short-term outcomes of 25 pediatric recipients of SOT who tested positive for SARS-CoV-2 during the first nine months of the epidemic in Israel.</div>

Results

<div style="direction: ltr;">The mean age was 15.2±4 years; 14 (56%) were kidney and 11 (44%) liver transplant recipients. Twenty-three (92%) of the patients were symptomatic. The most common symptoms were fever (44%), headache (44%), cough (40%), and fatigue (36%). Most (84%) had a mild disease. Two patients (8%), both kidney transplant recipients with additional comorbidities, had severe respiratory disease and required adjustments in their immunosuppression therapy. None were admitted to the pediatric intensive care unit or died, and all the patients fully recovered after a median of 27 [interquartile range 21-41] days. Significantly longer virus shedding time was found among kidney and pancreas transplanted recipients than among liver transplant recipients (35.1±9.8 vs.19.6±4.7 days, p=0.0005). Following a median of 7 (5-10.5) weeks after COVID-19 diagnosis, 3 (22%) reported residual symptoms, mainly fatigue; 22/23 (96%) had positive antibody responses.</div>

Conclusion

<div style="direction: ltr;">Our study demonstrated that while the majority of pediatric recipients of SOT developed a mild disease with a positive serologic response, a relatively high percentage (8%) developed a severe disease. This emphasizes the need for close monitoring of this particular population, especially those with comorbidities.</div>